You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

famitinib

Showing 1 - 25 of 47
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Thyroid Cancer Trial (20 mg Famitinib & 1200 mg Adebrelimab)

Not yet recruiting
  • Thyroid Cancer
  • 20 mg Famitinib & 1200 mg Adebrelimab
  • (no location specified)
Nov 26, 2023

TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Camrelizumab Plus Chemotherapy and Famitinib
  • Camrelizumab Plus Chemotherapy
  • (no location specified)
Aug 17, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Famitinib
  • +2 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 27, 2023

Solid Tumor Trial in Jinan (famitinib malate T(5 mg*4)?famitinib malate R(20 mg))

Active, not recruiting
  • Solid Tumor
  • famitinib malate T(5 mg*4)、famitinib malate R(20 mg)
  • Jinan, Jinan, China
    The First Affiliated Hospital of USTC
May 20, 2022

Healthy Subjects Trial (Famitinib)

Not yet recruiting
  • Healthy Subjects
  • Famitinib
  • (no location specified)
Jul 25, 2022

Triple-Negative Breast Cancer Trial in Shanghai (Camrelizumab plus Famitinib with/without nab-Palitaxel)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Camrelizumab plus Famitinib with/without nab-Palitaxel
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jan 2, 2023

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • SHR-1210
  • Famitinib
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Advanced Breast Cancer, Metastatic Breast Cancer Trial in Tianjin (SHR6390, famitinib)

Recruiting
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
Apr 6, 2022

Solid Tumor Trial in Changsha (Famitinib Malate Capsules)

Active, not recruiting
  • Solid Tumor
  • Famitinib Malate Capsules
  • Changsha, Hunan, China
    Xiangya Hospital Central South University
Oct 9, 2021

Solid Tumor Trial in Shanghai (Camrelizumab, Famitinib)

Active, not recruiting
  • Solid Tumor
  • Shanghai, Shanghai, China
    Fudan University Zhongshan Hospital
Feb 9, 2022

Advanced NSCLC Trial in Yangzhou (camrelizumab + famitinib, famitinib, docetaxel)

Recruiting
  • Advanced NSCLC
  • camrelizumab + famitinib
  • +2 more
  • Yangzhou, Jiangsu, China
    Subei People's Hospital of Jiangsu Province
Jan 11, 2022

Advanced Solid Tumors Trial in Shanghai (Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin

Recruiting
  • Advanced Solid Tumors
  • Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Apr 2, 2022

Tumor Trial (Fluconazole?Famitinib)

Not yet recruiting
  • Tumor
  • (no location specified)
Dec 6, 2021

Advanced Solid Tumor Trial in Tianjin (SHR-1802+camrelizumab + famitinib)

Recruiting
  • Advanced Solid Tumor
  • SHR-1802＋camrelizumab + famitinib
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute&Hospital
May 25, 2022

Metastatic Breast Cancer Trial in Zhengzhou (Famitinib, SHR6390, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • Famitinib
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jan 25, 2022

Cervical Cancer Trial in Shanghai (camrelizumab; famitinib malate, platinum-based chemo)

Enrolling by invitation
  • Cervical Cancer
  • camrelizumab； famitinib malate
  • platinum-based chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 12, 2021

Tumor Trial in Nanjing (famitinib?omeprazole)

Active, not recruiting
  • Tumor
  • Nanjing, Jiangsu, China
    Zhongda Hospital, Affiliated to Southest University
Nov 16, 2021

Healthy Adult Subjects Trial in Beijing (Famitinib malate)

Completed
  • Healthy Adult Subjects
  • Famitinib malate
  • Beijing, Beijing, China
    Xuanwu Hospital Beijing, Capital Medical University
Oct 19, 2021

ER+ / HER2- Advanced Breast Cancer Trial in Harbin (SHR6390?Famitinib)

Recruiting
  • ER+ / HER2- Advanced Breast Cancer
  • Harbin, Heilongjiang, China
    Harbin Medical University Cancer Hospital
Nov 25, 2021

Triple-Negative Breast Cancer Trial in Shanghai (camrelizumab in combination with nab-paclitaxel and famitinib)

Active, not recruiting
  • Triple-Negative Breast Cancer
  • camrelizumab in combination with nab-paclitaxel and famitinib
  • Shanghai, China
    Zhi-Ming Shao
Jan 7, 2022

NSCLC Trial in Shanghai (Camrelizumab, Famitinib)

Not yet recruiting
  • NSCLC
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Aug 5, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Famitinib)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Aug 23, 2021

Solid Tumor Trial in China (SHR-1701, Famitinib)

Recruiting
  • Solid Tumor
  • SHR-1701
  • Famitinib
  • Hefei, Anhui, China
  • +15 more
Jan 11, 2022

Intrahepatic Cholangiocarcinoma Trial (Famitinib)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • Famitinib
  • (no location specified)
Jun 16, 2021

Sarcomatoid Carcinoma of Lung Trial (Camrelizumab, Famitinib)

Not yet recruiting
  • Sarcomatoid Carcinoma of Lung
  • (no location specified)
May 12, 2021